LIPOSOME AS A DRUG DELIVERY CARRIER-A REVIEW

Rekha Kumari; Kuldeep Varma; Surabhi Srivastava; Jyoti Rai Prachya; Sheo Datta Maurya

doi:10.22270/ijdra.v1i1.2

Rekha Kumari Department of Pharmacy, IEC Group of Institutions, Knowledge Park.-I, Greater Noida, INDIA- 201308 *Corresponding Author’s E-mail: Rekha_
Kuldeep Varma Department of Pharmacy, IEC Group of Institutions, Knowledge Park.-I, Greater Noida, INDIA- 201308
Surabhi Srivastava Department of Pharmacy, IEC Group of Institutions, Knowledge Park.-I, Greater Noida, INDIA- 201308 *Corresponding Author’s E-mail: Rekha_
Jyoti Rai Prachya Department of Pharmacy, IEC Group of Institutions, Knowledge Park.-I, Greater Noida, INDIA- 201308
Sheo Datta Maurya Department of Pharmacy, IEC Group of Institutions, Knowledge Park.-I, Greater Noida, INDIA- 201308

DOI https://doi.org/10.22270/ijdra.v1i1.2

Abstract

The evolution of the science and technology of liposomes as a drug carrier has passed through a number of
distinct phases. Because they exhibit peculiar properties due to their structure, chemical composition
amphiphilic nature, physico-chemical characters and colloidal size, which are used in various applications.
These properties point to several applications as the solubilizer for insoluble drugs, dispersants, and sustained
release system, delivery system for the encapsulated substance, stabilizer, protective agents, and micro reactive
being the most obvious ones. Yet interest in liposomes, especially among academic workers, spread rapidly we
attribute this to the remarkable structural versatility of the system, which enables the design of countless
liposomes versions to satisfy particular needs in terms of both technology and optimal function in vivo.

Keywords: Liposomes, Liposomal vesicles, MLV, SUV, OLV, Phospholipid.

Downloads

Download data is not yet available.

References

1. Abraham W and Downing O. T., 1990; Biochim.
Biophys. Acta 1021, 119.
2. Crommelin OJA, Schreier H. 1994: Liposomes.
In: Krcuter J, cd. Colloidal Drug Delivery
systems. Marcel Dekker, Inc., 73-190.
3. Barenholz Y. 2001; Liposome application:
problems and prospects. Curl' Opin Colloid
Interface Sci 6:66-77.
4. Lasic D D., July 1998; Novel application of
liposomes, Tibtech, Vol.16.
5. Allen T. M., 1994; Trends Pharm. Sci. 15,215
6. Baidya S., Gupta B.K., 1998, High
Technology site-specific approach through
liposomal drug delivery system. Indian J
pharm sci, 32 (1), 35-37.
7. Swarbrick J, Boylan JC, Cds. 1994, Encyclopedia
or Pharmaceutical Technology, Vol. 9,NY:
Marcel Dekker: 1-39.
8. Storm G, Crommelin DJA. Quo Vadis? 1998,
Pharmaceutical Science and Technology 1:19-31.
9. Vyas .S P., Khar, R.K., 2004; Targeted and
Controlled drug delivery: Novel Carrier system;
first reprint edition, C.B.S. publications.
10. Bandak S, Gorcn D, Horowitz A, Tzcmach 0,
Gabizon A., 1999; Pharmacological studies of
cisplatin encapsulated in long-circulating
liposomes in mouse tumor models. Anticancer
drugs 10:911-920.
11. Gabizon A, Goren 0, Cohen R, Barenholz Y.
1998, Development or liposomal anthracyclines:
from basics to clinical applications. J Controlled
Release.
12. Lasic DD., 1993 Liposomes: From Physics to
Applications. Amsterdam: Elsevier.
13. Zhang YP, Ceh B. Lasic DD. 2001:Liposomics in
drug delivery. In: Polymcric Biomaterials. 2nd cd.
Chapter 29. Damitziu S, ed. New York: Marcel
Dekker, 783-821.
14. Zuidam NJ, Van Winden E, De Vrueh R,
Crommclin DJA. 2003, In: Torehilin VP, Weissig
V, eds. Liposomes: A Practical Approach. 2nd
Cd. Oxford University Press.
15. Vernooij EAAM, Keltencs-van den Bosch
EAAM, Underberg WJM, Crommelin DJA.
Chemical hydrolysis of DOTA and DOPE in a
Liposomal environment. Journal of Controlled
Release 2002: 79:299-303.
16. Daan J. A. Crommelin and Gert Storm, 2003,
Liposomes: From the Bench to the Bed; Journal
of Liposome research Vol. 13, No. I, pp. 33-36.